Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 27

Sort by

Sort Order Select

Journal Articles

Predictive Model and Factors of Relapse after Allogeneic Stem Cell Transplantation in Adults with Ph-Positive Acute Lymphoblastic Leukemia

Kseniia S. Afanaseva, Evgeny A. Bakin, Olga V. Pirogova, Elena V. Morozova, Ildar M. Barkhatov, Anna G. Smirnova, Sergey N. Bondarenko, Ivan S. Moiseev, Alexander D. Kulagin

Blood (2021) 138 (Supplement 1): 3934.

https://doi.org/10.1182/blood-2021-153763

Published: 2021

Journal Articles

Non-Intensive Continuous Treatment with a Tyrosine Kinase Inhibitor (TKI) Followed By Allo-HSCT Is an Effective Therapeutic Strategy for Adult Ph-Positive Acute Lymphoblastic Leukemia: Outcomes of the Russian Prospective Multicenter RALL Study

Olga A. Gavrilina, Elena N. Parovichnikova, Vera V. Troitskaya, Zalina Kh. Akhmerzaeva, Sergey N. Bondarenko, Valery A. Lapin, Maria E. Grishunina, Olga S. Samoylova, Tatiana S. Konstantinova, Larisa A. Kuzmina, Julia A. Chabaeva, Valery G. Savchenko

Blood (2021) 138 (Supplement 1): 4395.

https://doi.org/10.1182/blood-2021-153068

Published: 2021

Journal Articles

Gilteritinib Versus Salvage Chemotherapy for Relapsed/Refractory FLT3 -Mutated Acute Myeloid Leukemia: A Phase 3, Randomized, Multicenter, Open-Label Trial in Asia

Blood (2021) 138 (Supplement 1): 695.

https://doi.org/10.1182/blood-2021-145436

Published: 2021

Journal Articles

Invasive Aspergillosis in Allogeneic Hematopoietic Stem Cell Transplantation Recipients: A Large Cohort Single-Center Study

Yuliya A. Rogacheva, Vladislav V. Markelov, Marina O. Popova, Alisa G. Volkova, Ilya Y. Nikolaev, Olga N. Pinegina, Svetlana M. Ignatyeva, Tatiyana S. Bogomolova, Sergey N. Bondarenko, Nikolay N. Klimko, Alexander D. Kulagin

Blood (2021) 138 (Supplement 1): 1801.

https://doi.org/10.1182/blood-2021-153762

Published: 2021

Journal Articles

Early Hematopoietic Stem Cell Transplantation in the Treatment of High-Risk Infant Leukemia

Olesia V Paina, Zhemal Zarifovna Rakhmanova, Polina Valerievna Kozhokar, Anastasia Sergeevna Frolova, Luibov Alexandrovna Tsvetkova, Anastasia Svyatoslavovna Borovkova, Kirill Alexandrovich Ekushov, Inna Viktorovna Markova, Sergey N. Bondarenko, Elena V Babenko, Aleksandr L. Alyanski, Ildar M. Barkhatov, Elena Vladimirovna Semenova, Eugene A. Bakin, Aleksandr D. Kulagin, Ivan S. Moiseev, Ludmila S Zubarovskaya

Blood (2021) 138 (Supplement 1): 1850.

https://doi.org/10.1182/blood-2021-150279

Published: 2021

Journal Articles

Factors Affecting Post-Transplant Relapse of Acute Lymphoblastic Leukemia (ALL) in Children According on the Intensity of Conditioning

Elena Vladimirovna Semenova, PhD, Polina Valerievna Kozhokar, Dr., Olesia V Paina, PhD, Zhemal Zarifovna Rakhmanova, Dr., Anastasia S Frolova, Dr, Luibov Tsvetkova, Kirill Alexandrovich Ekushov, Dr., Tatiana A Bykova, MD PhD, Anna A. Osipova, Inna Markova, Sergey N. Bondarenko, Boris I Smirnov, Ildar M Barkhatov, MD PhD, Tatyana L. Gindina, Ivan S. Moiseev, Axel R. Zander, Ludmila S Zubarovskaya, MD PhD professor

Blood (2020) 136 (Supplement 1): 26–27.

https://doi.org/10.1182/blood-2020-139466

Published: 2020

Journal Articles

Predictive Model of Response to Blinatumomab Therapy in Children and Adults with Relapsed/Refractory B-ALL

Inna Markova, Sergey N. Bondarenko, Olesia V Paina, PhD, Anna A. Osipova, Bella I Ayubova, Eugene A. Bakin, Anna G. Smirnova, Elena Babenko, Elena Vladimirovna Semenova, PhD, Ivan S. Moiseev, Axel R. Zander, Ludmila S Zubarovskaya, MD PhD professor

Blood (2020) 136 (Supplement 1): 6–7.

https://doi.org/10.1182/blood-2020-140242

Published: 2020

Journal Articles

Risk Factors for Overall Survival in Children with High Risk Acute Myeloid Leukemia (HR AML) after Allogeneic Hematopoietic Stem Cell Transplantation (allo-HSCT) with Different Intensity of Conditioning Regimens

Elena Vladimirovna Semenova, PhD, Olesia V Paina, PhD, Zhemal Zarifovna Rakhmanova, Dr., Polina Valerievna Kozhokar, Dr., Anastasia S Frolova, Dr, Kirill Alexandrovich Ekushov, Dr., Tatiana A Bykova, MD PhD, Anna A. Osipova, Inna Markova, Sergey N. Bondarenko, Boris I Smirnov, Ildar M Barkhatov, MD PhD, Aleksandr Alyanski, Elena V. Babenko, Ivan S. Moiseev, Axel R. Zander, Ludmila S Zubarovskaya, MD PhD professor

Blood (2020) 136 (Supplement 1): 29.

https://doi.org/10.1182/blood-2020-137652

Published: 2020

Journal Articles

Comparison of FLU-BU12 Conditioning with the Standard BU-CY Myeloablative Regimen in High-Risk Pediatric ACUTE Myeloid Leukemia Patients Undergoing Allogeneic STEM Cell Transplantation

Olesia V Paina, PhD, Zhemal Zarifovna Rakhmanova, Dr., Polina Valerievna Kozhokar, Dr., Anastasia S Frolova, Dr, Liubov A. Tsvetkova, tsvetluibov@mail.ru, Kirill Alexandrovich Ekushov, Dr., Inna Markova, Sergey N. Bondarenko, Elena V. Babenko, Aleksandr L. Alyanskiy, aalyanskiygmail.com, Ildar M Barkhatov, MD PhD, Elena Vladimirovna Semenova, PhD, Aleksandr D. Kulagin, MD PhD, Ivan S. Moiseev, Ludmila S Zubarovskaya, MD PhD professor

Blood (2020) 136 (Supplement 1): 30–31.

https://doi.org/10.1182/blood-2020-139169

Published: 2020

Journal Articles

CC-486 Improves Overall Survival (OS) and Relapse-Free Survival (RFS) for Patients with Acute Myeloid Leukemia (AML) in First Remission after Intensive Chemotherapy (IC), Regardless of Amount of Consolidation Received: Results from the Phase III QUAZAR AML-001 Maintenance Trial

Andrew Wei, MBBS,PhD, Gail J. Roboz, MD, Hervé Dombret, MD, Hartmut Döhner, Andre C. Schuh, Pau Montesinos, MD PhD, Christopher Pocock, MBBS, Dominik Selleslag, MD, Sergey N. Bondarenko, Ignazia La Torre, Barry Skikne, MD, Keshava Kumar, PhD, Qian Dong, DrPH, C.L. Beach, PharmD, Farhad Ravandi, MBBS

Blood (2020) 136 (Supplement 1): 38–40.

https://doi.org/10.1182/blood-2020-138498

Published: 2020

Journal Articles

The Outcome of Patients with Advanced Phase Chronic Myeloid Leukemia with and without Allogeneic Hemopoietic Stem Cell Transplantation

Elena V. Morozova, Julia J. Vlasova, Maria V. Barabanshikova, Axel R. Zander, Ksenia Jurovskaya, Tatyana L. Gindina, Ildar Barhatov, Sergey N. Bondarenko, Ivan S. Moiseev, Ludmila S Zubarovskaya, MD PhD professor, Aleksandr D. Kulagin, MD PhD

Blood (2020) 136 (Supplement 1): 29–30.

https://doi.org/10.1182/blood-2020-139452

Published: 2020

Journal Articles

Allogeneic Hematopoietic Stem Cell Transplantation (allo-HSCT) with Different Intensity Conditioning Regimens in Children with Very High Risk Acute Lymphoblastic Leukemia (VHR ALL): A Single-Center Experience

Elena Vladimirovna Semenova, MD PhD, Olesia V Paina, PhD, Zhemal Zarifovna Rakhmanova, Dr., Polina Valerievna Kozhokar, Dr., Anastasia S Frolova, Dr, Kirill Alexandrovich Ekushov, Dr., Tatiana A Bykova, MD PhD, Anna Osipova, Inna V Markova, Dr., Sergey N. Bondarenko, PhDMD, Ildar Barhatov, Aleksandr Alyanski, Elena Babenko, Ivan S Moiseev, MD PhD, Ludmila S Zubarovskaya, MD PhD professor, Axel Zander, Boris V Afanasyev, MD PhD professor

Blood (2019) 134 (Supplement_1): 2050.

https://doi.org/10.1182/blood-2019-128163

Published: 2019

Journal Articles

Comparison of Allogeneic Transplant Outcomes Using Conditioning with Different Dose of Busulfan for Children with Acute Myeloid Leukemia

Olesia V Paina, PhD, Zhemal Zarifovna Rakhmanova, Dr., Polina Valerievna Kozhokar, Dr., Anastasia S Frolova, Dr, Kirill Alexandrovich Ekushov, Dr., Luibov Tsvetkova, Tatiana A Bykova, MD PhD, Inna V Markova, Dr., Sergey N. Bondarenko, PhDMD, Ildar M Barkhatov, MD PhD, Aleksandr Alyanski, Elena Babenko, Ivan S Moiseev, MD PhD, Marina O Popova, MD PhD, Elena Vladimirovna Semenova, MD PhD, Ludmila S Zubarovskaya, MD PhD professor, Axel Zander, Boris Afanasyev

Blood (2019) 134 (Supplement_1): 4510.

https://doi.org/10.1182/blood-2019-128155

Published: 2019

Journal Articles

Interim Results of Russian Acute Lymphoblastic Leukemia (RALL-2016) Study with Centralized MRD-Monitoring and Randomization for Autologous HSCT with Non-Myeloablative Conditioning in Adult Ph-Negative ALL Patients

Blood (2019) 134 (Supplement_1): 5072.

https://doi.org/10.1182/blood-2019-124701

Published: 2019

Journal Articles

Graft-Versus Host Disease Prophylaxis with Postransplantation Bendamustine in Refractory Leaukemia Patients

Ivan S Moiseev, MD PhD, Sergey N. Bondarenko, PhDMD, Elena I Darskaya, MD PhD, Aleksandr Alyanski, Evgeniya Borzenkova, Anna Dotcenko, Olga Kudyasheva, MD, Sergey Lapin, MD PhD, Elena Surkova, PhD, Varvara Nikolaevna Ovechkina, Olga Vladislavovna Pirogova, MD PhD, Valentina Vladimirovna Porunova, MD, Axel Zander, Boris Afanasyev

Blood (2019) 134 (Supplement_1): 5746.

https://doi.org/10.1182/blood-2019-125570

Published: 2019

Journal Articles

MRD Status Did Not Correspond to the Relapse Incidence within One Year of Follow-up By Non-Intensive but Non-Interruptive Approach: The First Interim Results of the Russian Prospective Multicenter RALL-2016 Trial for Ph-Negative Adult ALL

Blood (2018) 132 (Supplement 1): 5185.

https://doi.org/10.1182/blood-2018-99-116318

Published: 2018

Journal Articles

Persistence of the Minimal Residual Disease at the End of Induction Is Not a Factor of Poor Prognosis If Imatinib Was Changed to the Dasatinib By Ph+ RALL Protocol in Ph-Positive Acute Lymphoblastic Leukemia Patients

Olga A. Gavrilina, MDPhD, Elena N. Parovichnikova, MD PhD, Vera V. Troitskaya, MD PhD, Larisa A. Kuzmina, MD PhD, Sergey N. Bondarenko, PhDMD, Valery Lapin, Tatiana N. Obukhova, MD PhD, Andrey Sudarikov, PhD, Valery G. Savchenko, MD PhD academician

Blood (2017) 130 (Supplement 1): 2714.

https://doi.org/10.1182/blood.V130.Suppl_1.2714.2714

Published: 2017

Journal Articles

The Efficacy and Toxicity of Blinatumomab in Patients with Relapsed/Refractory Acute Lymphoblastic Leukemia: Russian Multicenter Experience

Blood (2017) 130 (Supplement 1): 2604.

https://doi.org/10.1182/blood.V130.Suppl_1.2604.2604

Published: 2017

Journal Articles

Blinatumomab + Tyrosine Kinase Inhibitors with No Chemotherapy in BCR-ABL-Positive or IKZF1-Deleted or FLT3-ITD-Positive Relapsed/Refractory Acute Lymphoblastic Leukemia Patients: High Molecular Remission Rate and Toxicity Profile

Andrey N. Sokolov, MD, Elena N. Parovichnikova, MD PhD, Vera V. Troitskaya, MD PhD, Larisa A. Kuzmina, MD PhD, Irina V. Galtseva, Sergei M. Kulikov, PhD, Sergey N. Bondarenko, PhDMD, Julia O. Davidova, Nikolay M. Kapranov, Irina A. Lukyanova, MD, Tatiana I. Lobanova, MD, Ekaterina I. Usikova, MD, Ksenija I. Zarubina, MD, Valeriy G. Savchenko

Blood (2017) 130 (Supplement 1): 3884.

https://doi.org/10.1182/blood.V130.Suppl_1.3884.3884

Published: 2017

Journal Articles

Graft-Versus-Host Disease Prophylaxis with Posttransplantation Cyclophosphamide and Ruxolitinib in Patients with Myelofibrosis

Elena V Morozova, MDPhD, Ivan S Moiseev, MD PhD, Maria V Barabanshikova, MDPhD, Elena I Darskaya, MDPhD, Sergey N. Bondarenko, PhDMD, Ludmila S Zubarovskaya, MD PhD Professor, Vadim Baykov, Alexandr L Alyanski, Ildar M Barkhatov, MD PhD, Axel R. Zander, MD PhD Professor, Boris V Afanasyev, MD PhD Professor

Blood (2017) 130 (Supplement 1): 4492.

https://doi.org/10.1182/blood.V130.Suppl_1.4492.4492

Published: 2017

NARROW

Predictive Model and Factors of Relapse after Allogeneic Stem Cell Transplantation in Adults with Ph-Positive Acute Lymphoblastic Leukemia

Non-Intensive Continuous Treatment with a Tyrosine Kinase Inhibitor (TKI) Followed By Allo-HSCT Is an Effective Therapeutic Strategy for Adult Ph-Positive Acute Lymphoblastic Leukemia: Outcomes of the Russian Prospective Multicenter RALL Study

Gilteritinib Versus Salvage Chemotherapy for Relapsed/Refractory FLT3 -Mutated Acute Myeloid Leukemia: A Phase 3, Randomized, Multicenter, Open-Label Trial in Asia

Invasive Aspergillosis in Allogeneic Hematopoietic Stem Cell Transplantation Recipients: A Large Cohort Single-Center Study

Early Hematopoietic Stem Cell Transplantation in the Treatment of High-Risk Infant Leukemia

Factors Affecting Post-Transplant Relapse of Acute Lymphoblastic Leukemia (ALL) in Children According on the Intensity of Conditioning

Predictive Model of Response to Blinatumomab Therapy in Children and Adults with Relapsed/Refractory B-ALL

Risk Factors for Overall Survival in Children with High Risk Acute Myeloid Leukemia (HR AML) after Allogeneic Hematopoietic Stem Cell Transplantation (allo-HSCT) with Different Intensity of Conditioning Regimens

Comparison of FLU-BU12 Conditioning with the Standard BU-CY Myeloablative Regimen in High-Risk Pediatric ACUTE Myeloid Leukemia Patients Undergoing Allogeneic STEM Cell Transplantation

CC-486 Improves Overall Survival (OS) and Relapse-Free Survival (RFS) for Patients with Acute Myeloid Leukemia (AML) in First Remission after Intensive Chemotherapy (IC), Regardless of Amount of Consolidation Received: Results from the Phase III QUAZAR AML-001 Maintenance Trial

The Outcome of Patients with Advanced Phase Chronic Myeloid Leukemia with and without Allogeneic Hemopoietic Stem Cell Transplantation

Allogeneic Hematopoietic Stem Cell Transplantation (allo-HSCT) with Different Intensity Conditioning Regimens in Children with Very High Risk Acute Lymphoblastic Leukemia (VHR ALL): A Single-Center Experience

Comparison of Allogeneic Transplant Outcomes Using Conditioning with Different Dose of Busulfan for Children with Acute Myeloid Leukemia

Interim Results of Russian Acute Lymphoblastic Leukemia (RALL-2016) Study with Centralized MRD-Monitoring and Randomization for Autologous HSCT with Non-Myeloablative Conditioning in Adult Ph-Negative ALL Patients

Graft-Versus Host Disease Prophylaxis with Postransplantation Bendamustine in Refractory Leaukemia Patients

MRD Status Did Not Correspond to the Relapse Incidence within One Year of Follow-up By Non-Intensive but Non-Interruptive Approach: The First Interim Results of the Russian Prospective Multicenter RALL-2016 Trial for Ph-Negative Adult ALL

Persistence of the Minimal Residual Disease at the End of Induction Is Not a Factor of Poor Prognosis If Imatinib Was Changed to the Dasatinib By Ph+ RALL Protocol in Ph-Positive Acute Lymphoblastic Leukemia Patients

The Efficacy and Toxicity of Blinatumomab in Patients with Relapsed/Refractory Acute Lymphoblastic Leukemia: Russian Multicenter Experience

Blinatumomab + Tyrosine Kinase Inhibitors with No Chemotherapy in BCR-ABL-Positive or IKZF1-Deleted or FLT3-ITD-Positive Relapsed/Refractory Acute Lymphoblastic Leukemia Patients: High Molecular Remission Rate and Toxicity Profile

Graft-Versus-Host Disease Prophylaxis with Posttransplantation Cyclophosphamide and Ruxolitinib in Patients with Myelofibrosis

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only